Evidence map›Paper›PMID 38781188›Full record

ArticlePloS one2024

Usefulness of assessment of the Clinical Frailty Scale and the Dementia Assessment Sheet for Community-based Integrated Care System 21-items at the time of initiation of maintenance hemodialysis in older patients with chronic kidney disease.

Seiji Hashimoto, Mitsuyo Itabashi, Kenta Taito, Ayano Izawa, Yui Ota, Takaaki Tsuchiya, Shiho Matsuno, Masahiro Arai, Noriko Yamanaka, Takako Saito and 4 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Seiji HashimotoDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.ORCID 0000-0003-4131-6151
Mitsuyo ItabashiDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Kenta TaitoDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Ayano IzawaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Yui OtaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Takaaki TsuchiyaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Shiho MatsunoDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Masahiro AraiDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Noriko YamanakaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Takako SaitoDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Masatoshi OkaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Noriyuki SuzukiDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Yuki TsurutaDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.
Takashi TakeiDepartment of Nephrology and Dialysis, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi, Tokyo, Japan.ORCID 0000-0002-6283-8146

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe examined whether the Clinical Frailty Scale (CFS), a widely adopted tool for stratifying the degree of frailty, and the Dementia Assessment Sheet for Community-based Integrated Care System 21-items (DASC-21), a simple tool for simultaneous assessment of impaired cognition and impaired ADL, at the time of initiation of hemodialysis is useful tool of older patients for the outcome and prognosis.

methodsData for 101 patients aged 75 years or older (mean age, 84.3 years) with ESRD who were initiated on hemodialysis and could be followed up for a period of 6 months were reviewed.

resultsThe 6-month survival curves showed a significantly higher number of deaths in the frailty (CFS≥5) group than in the normal to vulnerable (CFS<5) group (p<0.01). The CFS level was also significantly higher (6.5±1.5) in patients who died within 6 months of dialysis initiation as compared with that (4.6±1.7) in patients who survived (p<0.01). On the other hand, the total score of DASC-21 was related to need for inpatient maintenance dialysis (p<0.01). The total score on the DASC-21 were found as showing significant correlations with the CFS level. The IADL outside the home was identified in the DASC-21 sub-analyses as being correlated with CFS.

conclusionsThe CFS and the DASC-21 appeared to be a useful predictive tool of outcome and prognosis for older patients being initiated on hemodialysis. Assessment by the CFS or the DASC-21 might be useful for selecting the renal replacement therapy by shared decision-making and for advance care planning.

Indexed as

DementiaFrailtyRenal DialysisRenal Insufficiency, ChronicAgedAged, 80 and overDelivery of Health Care, IntegratedFemaleGeriatric AssessmentHumansKidney Failure, ChronicMalePrognosis

Identifiers

PMID38781188
PMCPMC11115207

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.